Drugs / TRIDECANOATE
TRIDECANOATE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03059160 | Apr 2017 → Apr 2018 | Rett syndrome | Sheba Medical Center | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRIDECANOATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL107874 ↗ |
| Known as | Tridecanoic Acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03059160 ↗ |
| Known as | Tridecanoic acid anion | ChEMBL registry synonym — accepted as the source's own label CHEMBL107874 ↗ |
| Modality | Small molecule | — CHEMBL107874 ↗ |
| Route | Oral | “3 times daily oral doze of the drug for 20 weeks with 4 weeks of baseline and 4 weeks of washout” NCT03059160 ↗ |